By Kyle Morris

 

AstraZeneca PLC said Monday that a Lynparza combination has been recommended for marketing authorization in the European Union for the treatment of metastatic castration-resistant prostate cancer.

The Anglo-Swedish pharma major said Lynparza in combination with abiraterone and prednisone or prednisolone has been recommended by the Committee for Medicinal Products for Human Use of the European Medicines Agency for the treatment of adult patients for whom chemotherapy isn't clinically indicated.

 

Write to Kyle Morris at kyle.morris@dowjones.com

 

(END) Dow Jones Newswires

November 14, 2022 02:29 ET (07:29 GMT)

Copyright (c) 2022 Dow Jones & Company, Inc.
Astrazeneca (LSE:AZN)
過去 株価チャート
から 12 2022 まで 1 2023 Astrazenecaのチャートをもっと見るにはこちらをクリック
Astrazeneca (LSE:AZN)
過去 株価チャート
から 1 2022 まで 1 2023 Astrazenecaのチャートをもっと見るにはこちらをクリック